These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26194764)

  • 1. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
    Donadieu J; Bernard F; van Noesel M; Barkaoui M; Bardet O; Mura R; Arico M; Piguet C; Gandemer V; Armari Alla C; Clausen N; Jeziorski E; Lambilliote A; Weitzman S; Henter JI; Van Den Bos C;
    Blood; 2015 Sep; 126(12):1415-23. PubMed ID: 26194764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
    DU Y; Xiong H; Li H; Li JX; Tao F; Yang L; Lu WJ; Qi SS; Zhang LN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):943-949. PubMed ID: 35680831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis].
    Hu T; Liu R; Li J; Cao J; Zhang L; Li J; Fan W; Zhong D; Shi X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):985-9. PubMed ID: 25417874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of intermediate-dose cytarabine in the treatment of children with refractory high risk Langerhans cell histiocytosis].
    Wang WQ; Ge J; Ma HH; Lian HY; Cui L; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2023 Dec; 61(12):1118-1123. PubMed ID: 38018049
    [No Abstract]   [Full Text] [Related]  

  • 5. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine.
    Choi SW; Bangaru BS; Wu CD; Finlay JL
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):503-6. PubMed ID: 12794533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk organ + LCH gets the one-two punch?
    Stine KC
    Blood; 2015 Sep; 126(12):1399-400. PubMed ID: 26384280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Langerhans cell histiocytosis, a case of Letterer Siwe disease.
    Pant C; Madonia P; Bahna SL; Bass PF; Jeroudi M
    J La State Med Soc; 2009; 161(4):211-2. PubMed ID: 19785312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
    Néel A; Artifoni M; Fontenoy AM; Tessoulin B; Lorillon G; Cohen-Aubart F; Haroche J; Genereau T; de Menthon M; Guillevin L; Maillard H; Kahn JE; Hermine O; Araujo C; Dromer C; Jullien D; Hamidou M; Donadieu J; Tazi A
    Br J Haematol; 2020 Jun; 189(5):869-878. PubMed ID: 32191819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
    Evseev D; Osipova D; Kalinina I; Raykina E; Ignatova A; Lyudovskikh E; Baidildina D; Popov A; Zhogov V; Semchenkova A; Litvin E; Kotskaya N; Cherniak E; Voronin K; Burtsev E; Bronin G; Vlasova I; Purbueva B; Fink O; Pristanskova E; Dzhukaeva I; Erega E; Novichkova G; Maschan A; Maschan M
    Blood Adv; 2023 Sep; 7(18):5246-5257. PubMed ID: 37216396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
    J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cladribine treatment of repeatedly-relapsed Langerhans cell histiocytosis: a case report and literature review].
    Yao X; Ying H; Weihong Z; Qing S; Xintian L
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):296-9. PubMed ID: 26182506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
    Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
    BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
    Apollonsky N; Lipton JM
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis.
    Rosso DA; Amaral D; Latella A; Chantada G; Braier JL
    Br J Haematol; 2016 Jan; 172(2):287-90. PubMed ID: 25944303
    [No Abstract]   [Full Text] [Related]  

  • 17. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
    Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J
    Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
    Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
    Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients].
    Grau J; Ribera JM; Tormo M; Indiano JM; Vercher J; Sandoval V; Ramírez G; Sastre A; Flores E; García-Conde J
    Med Clin (Barc); 2001 Mar; 116(9):339-42. PubMed ID: 11333766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The global challenge of treating disseminated LCH.
    Gulati N
    Pediatr Hematol Oncol; 2020 Nov; 37(8):653-655. PubMed ID: 33439096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.